Cygenics contract with DOD renewed

By Melissa Trudinger
Wednesday, 16 February, 2005

Singapore-based Cygenics (ASX: CYN) has announced that the US Department of Defence had renewed its screening service contract with the company's US-based subsidiary Cytomatrix.

The renewal of the contract means that the company will receive the more than US$1 million remaining from the original contract which was valued at $1.684 million.

The DOD is using Cytomatrix's three-dimensional cell growth scaffold technology for the production of T cells that can be used to screen vaccine prototypes under development, allowing assessment of in vivo activity in an in vitro system.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd